Apologies for the technical difficulties, and welcome to Mativ's third quarter 2025 earnings conference call. On the call today for Mativ are Shruti Singhal, Chief Executive Officer, Greg Weitzel, Chief Financial Officer, and Chris Kuepper, Director of Investor Relations. Today's call is being recorded and will be available for replay later this afternoon. At this time, all participants have been placed in a listen-only mode, and the floor will be open for your questions following the presentation. If you would like to ask a question at that time, please press Star 1 on your touch-tone phone. If you need to remove yourself from the queue, please press the pound key. If you require operator assistance, please press Star 0. We ask that you please pick up your handset to allow optimal sound quality. It is now my pleasure to turn the call over to Mr. Chris Kuepper. Sir, you may begin. Good morning, everyone, and thank you for joining us for Mativ's third quarter 2025 earnings call. Before we begin, I'd like to remind you that comments included in today's conference call include forward-looking statements. Actual results may differ materially from these comments for reasons shown in detail in our Securities and Exchange Commission filings, including our annual report on Form 10-K and our quarterly reports on Form 10-Q. Some financial metrics discussed during this call are non-GAAP financial metrics. Reconciliations of these metrics to the closest GAAP metrics are included in the appendix of the earnings release. Unless stated otherwise, financial and operational metric comparisons are to the prior year period and relate to continuing operations. The earnings release issued yesterday afternoon and the accompanying slide deck are available on our website at irr.mativ.com. With that, I'll turn the call over to Shruti. Thanks, Chris. Good morning, everyone, and thank you for joining our call. I'm pleased to report that we delivered another quarter that exceeded our expectations, with overall year-over-year improvement in our top-line and bottom-line results. On our last earnings call in August, we communicated our expectations for Adjusted EBITDA to be 5%-10% higher in Q3 year-over-year, and for Q3 cash flow to be favorable as well versus prior year. As you saw in our Q3 earnings release, Adjusted EBITDA came in 10% higher at the top end of that range, and we doubled free cash flow versus last year on a year-to-date basis. As a matter of fact, if you take both Q2 and Q3 together, this has been our strongest six-month period since the merger on both an Adjusted EBITDA and free cash flow basis, demonstrating that the decisions we made earlier this year are working and are delivering a step change to our financials at almost every level. On a consolidated basis, Adjusted EBITDA of $66.8 million was up $6 million over Q3 of 2024. While sales of $513 million were up over 5% on an organic basis and 3% higher on a reported basis versus last year. This is a true testament to the strength and effectiveness of our salesforce, who are finding new and creative solutions to serve our customers with their unmet needs. Free cash flow came in at $66.7 million, which is $42 million higher year-over-year. Q3 free cash flow was also sequentially better by $17 million, making Q3 of 2025 now the second-highest cash flow quarter since the merger. I'm very proud and energized by our global team's outstanding performance. While our demand environment continues to be challenging as tariffs and macroeconomic policies constantly change how we operate in the market, our global Mativ team continues to show resilience and a strong commitment to driving commercial and operational excellence. Thank you to the entire Mativ team for embracing these changes and executing to our strategic imperatives. Let me touch briefly on our segment results. SAS sales continued their strong momentum from the previous quarters and were up 5% on an organic basis, the sixth consecutive quarter of year-over-year improvement in sales. SAS showed solid improvement across all categories, with tapes and labels, liners, and healthcare up mid to high single digits versus last year, and paper and packaging up low single digits. Our SAS commercial teams are driving incremental annual revenue in construction tapes with strategic distributor partners, cable tapes with an energy and telecom company, personal care liners with a global consumer goods company, and incremental holiday display features with a mass retail chain. We also saw strong incremental demand from label converters and also in our consumer tape and healthcare categories. Additionally, we are driving market share gains in cable tapes, commercial print, and consumer paper, and we are realizing cross-selling opportunities across our tapes and liners businesses. SAS Adjusted EBITDA for the quarter was $48.3 million, up $7 million or over 17% versus prior year, while Q3 also represented our strongest SAS Adjusted EBITDA margin since the merger at 15.3%, which was up 200 basis points year-over-year. SAS EBITDA and margin performance drove the majority of the improvement in our consolidated EBITDA and margin this quarter. In our FAM segment, we marked a significant turnaround point. Q3 was the first quarter of growth in sales and Adjusted EBITDA since the merger. FAM sales of $198 million increased by more than $8 million or over 4% from last year. This achievement reinforces our confidence in the effectiveness of our proven SAS go-to-market strategy across the FAM segment. We expect FAM to continue to compare favorably on a year-over-year basis in Q4 as well. While overall demand patterns continue to be mixed and challenged in the construction and automotive sectors, we saw continued pockets of growth with filtration up high single digits driven by water, HVAC, and air pollution control. While in films, we are regaining business and continue to make meaningful progress towards closing the year-over-year comparison gap. Our FAM teams have driven 20%+ growth in HVAC, air pollution control markets, and almost 10% growth in water filtration with significant increases in customer commitments. We also achieved above-market growth for transportation filtration and erosion control, as well as growth in medical films. As announced earlier this year, we have had a clear focus on three critical strategic priorities: driving enhanced commercial execution, strengthening our balance sheet, and conducting a strategic review of our portfolio. These priorities are propelling meaningful results in our operations and financial performance, allowing us to stay focused on the areas that we can control. At the same time, we are developing strategies for the prevailing macro uncertainties and have multiple actions underway to enable a more agile operating model, grow our market shares, provide growth opportunities for our employees, and deliver long-term value creation for shareholders. A key component of driving enhanced commercial execution is the ability to successfully execute pricing initiatives. We are very focused on maintaining a positive price versus input cost relationship, and our Q3 results show the outcome of that effort. We have formalized our pricing efforts through the development of a pricing process that is governed by a steering committee. The regular cadence of this committee will help ensure pricing structures are in line with prevailing market dynamics as well as input and associated labor costs. Furthermore, our dedicated sales teams are continuing to expand our pipeline by working with our customers to complement current relationships with solutions that address their unmet needs, whether that is via the Mativ integration of another step in their value chain, a geographic supply chain solution, or multiple Mativ category solutions across the broader enterprise. Our customers value our localized supply chain and our flexibility to partner with them how and where they go to market, and this ability is reflected in the number of long-term agreements we have been able to renew, as well as incremental commitments we were able to book with existing and new customers. When it comes to strengthening our balance sheet, earlier this year, we announced a number of initiatives to reduce our cost structure and capital expenditures and optimize our working capital levels. Those actions have driven quantifiable improvements in our margin and cash flow levels over the past two quarters and are materially reducing our leverage. Year-to-date, we have already delivered twice the amount of free cash flow as compared to full year 2024, and we expect our leverage to continue improving over the coming months and quarters. Within our strategic portfolio review, we have executed on initiatives such as optimizing the footprint of our operations support structure and SKU rationalization. Also, over the past quarter, we have been working through an R&D optimization initiative to help allocate the right resources to our most worthwhile projects. We have prioritized our R&D projects towards those that are accredited in the near term while exceeding our ROI benchmarks. In doing so, we lowered our overall R&D spend with limited impact to our commercial pipeline, and we are working to leverage resources more effectively going forward. As part of this portfolio review, in early October, we made the strategic decision to close our Wilson, North Carolina, facility. Our intent is to wind down operations over the next couple of months, transition existing customers and employees, and close the facility by the end of Q4. We expect this closure to be accredited to earnings starting in Q1 2026. We now operate a total of 34 sites across the globe versus 48 at the time of the merger, and we will continue to look at opportunities to improve the operational performance of our sites with the lessons learned from our continuous quality and process improvement initiatives. Our strategic review process is still underway, with many workstreams making good progress over the past six months since we kicked it off. It remains a key part of our focus this year, and we look forward to keeping you updated on this effort as we continue to make progress. On the operations front, we have several manufacturing, supply chain excellence, and continuous improvement workstreams underway. We have enhanced efficiency at multiple sites by increasing machine speeds on key production lines, all while maintaining our high standards of quality. Product quality improvements in many of our sites have also materially reduced scrap byproducts, and our continuous process improvement initiatives have reduced changeover times and increased yields and machine uptimes. We will continue rolling out these improvements to other sites throughout Q4 and beyond to leverage the benefits and accelerate improvements. We at Mativ embrace safety as a number one value. Our safety programs over the past 12 months have successfully lowered injury rates by more than 15% and further removed significant risks across our global operations. We maintain strategic alignment by working directly with each site via our operational leaders through education, guidance, and support in setting safety priorities, keeping each site accountable through our safety balance scorecard indicator. On the supply chain side, we are continuing to streamline our portfolio of products and number of SKUs, and we are cross-sourcing across the globe to minimize our tariff exposures. As a result of these actions, our continued USMCA exemptions and the recent updated tariff announcement, currently less than 6% of our sales are subject to tariffs. We continue to mitigate and offset any new tariff impacts on our business as well. Our distribution expenses have been elevated over the past two quarters as we are cross-sourcing certain products across the Atlantic that would otherwise be subject to tariffs. We have a set of operational improvements underway to offset our distribution expenses, which include warehouse footprint optimization, a transportation management system that is now live in several of our U.S. locations, and optimized freight quote management with our spot freight providers. As you can see, there is a lot going on here at Mativ to navigate the challenging demand environment, broaden our customer base, and transform us into a more agile entity that is primed for long-term success and value creation. I'll now turn it over to Greg to provide additional color on how these initiatives have impacted our financial performance in Q3 and our expectations for the remainder of the fiscal year. Thanks, Shruti, and good morning, everyone. Consolidated net sales from continuing operations for the quarter were $513 million, up 3% compared to $498 million in the prior year on a reported basis, and up $25 million, or 5%, on an organic basis, as increases for both segments in volume mix and currency, as well as SAS selling prices, were partially offset by slightly unfavorable FAM selling prices. Adjusted EBITDA from continuing operations was $66.8 million, up 10% from $60.8 million in the prior year. Favorable net selling price versus input cost, higher organic volume, and lower manufacturing costs represented a combined $8 million favorable impact, which was partially offset by a combined $2 million of higher distribution and SG&A cost. Price versus input cost performance turned positive for the quarter, as communicated on the Q2 call, and is expected to be favorable in Q4 as well. Adjusted EPS were $0.39 a share versus $0.21 a share in the prior year period. Turning to each of our segments, net sales in our Filtration and Advanced Materials segment of $198 million were up 4% versus Q3 of 2024. The year-over-year increase was produced by higher volume mix and favorable currency translation, partially offset by lower selling prices. FAM Adjusted EBITDA of $37 million increased slightly year-over-year, reflecting the effects of higher volume mix, partially offset by higher manufacturing costs. In our Sustainable and Adhesive Solutions segment, net sales of $315 million were up more than $16 million, or 5%, on an organic basis, and increased by just over $6 million, or 2%, from last year on a reported basis. Organic growth was driven by higher volumes across key categories and higher selling prices across the segment, along with favorable currency translation. SAS Adjusted EBITDA performance of $48 million increased 17% year-over-year from $41 million in the prior year. The year-over-year performance resulted from favorable net selling price versus input cost performance, lower manufacturing cost, and lower SG&A expenses, partially offset by unfavorable mix and higher distribution costs. Turning to a few of the corporate items, unallocated corporate Adjusted EBITDA expense of $18 million increased by just under $2 million versus the prior year due to the timing of employee-related expenses. Interest expense of just under $18 million decreased slightly versus the prior year. When taking hedges into account, over 80% of our debt is at a fixed rate and matures on a staggered basis between 2027 and 2029. Other expense was $3.9 million in the current period and decreased over $8 million, with the impact from losses on asset sales and unfavorable foreign currency being more prominent in the prior year period. Our tax rate was a 43% benefit in the quarter, driven by a one-time adjustment and mix of earnings. At the end of the quarter, net debt was $932 million, a reduction of more than $60 million versus last quarter, and available liquidity was $517 million. Our net leverage ratio, as defined in our credit agreement, has been reduced to 4.2x, and we expect to be even closer to the 4x level by the end of the year. Deleveraging will continue to be our highest priority for cash flow utilization. With that in mind, as discussed on previous earnings calls, we have strategic initiatives underway to materially improve cash flow generation and will continue this focus as we head into 2026. As a reminder, those initiatives are comprised of pricing actions as well as cost optimization initiatives. We are targeting $35 million-$40 million of cost savings by year-end 2026, with $15 million-$20 million realized and flowing through the P&L in 2025. We are on track to manage our capital expenditures to $40 million in 2025. We continue to work to reduce our year-end inventory levels by $20 million in 2025 versus 2024. Working capital is expected to remain a source of cash of approximately $10 million for the full year 2025. Taken together, all of these efforts and initiatives have made Q2 and Q3 of 2025 two of our highest cash flow quarters since the merger. Free cash flow for Q3 was $66 million, more than twice the amount we generated in Q3 of 2024. Our year-to-date free cash flow of $85 million is also more than twice the amount we generated year-to-date in 2024, and early realization of our expectations for the full year cash flow to double our 2024 levels. As a reminder, our Q4 cash flow levels are generally much lower due to our usual year-end seasonality, and we expect Q4 cash flow to be similar to prior year. We do, however, expect our working capital initiatives to contribute to strong free cash flow generation in 2026 and beyond. As we look ahead, we acknowledge that market demand remains uncertain, with additional impacts from tariffs and macroeconomic policy in the market impacting our levels of sales and operating leverage. However, with the positive momentum we have seen through early November across key categories in FAM and SAS, combined with our strategic initiatives, we expect our Q4 Adjusted EBITDA to increase by at least 10% versus last year. This step-up will be driven by a year-over-year increase in volume, particularly on the SAS side, favorable relative net selling price versus input cost, operational improvements, and cost savings. For modeling purposes, for the full year 2025 on the tariff front, with all the recent announcements throughout the quarter, we are updating our guidance to now state that less than 6% of our annual sales are currently subject to tariffs. The previous guidance covered 7% of our annual sales. With that, Shruti, I'll hand it back to you for your closing remarks. Thank you, Greg. What everyone should take away from this call is that we are proud of the progress we have made and the results we have delivered in Q3. The strength of our sales-Adjusted EBITDA and free cash flow performance, particularly over the past six months, demonstrates the effectiveness of our strategic decisions and the resilience of our business model. Our teams continue to execute with discipline and agility, driving commercial and operational excellence across both segments. While the macro environment remains dynamic, we are focused on the factors within our control, and we are taking proactive steps to position Mativ for long-term success. Our strategic priorities, as communicated last quarter, driving enhanced commercial execution, sharpening efforts to delever the balance sheet, and conducting a strategic portfolio review have not changed and are front and center. Our company-wide pivot towards a higher sense of urgency and faster pace of execution are yielding measurable results and are solidifying the foundation for generating continued value for our customers, employees, and shareholders. Thank you for joining us this morning. Operator, please open the line for questions. Thank you very much. If you would like to ask a question, please press star followed by one on your telephone keypad. When prepping to ask your question, please ensure your device is unmuted locally. If you change your mind or your question has already been answered, press star followed by two. Our first question comes from Daniel Harriman with Sidoti. Your line is now open. Please go ahead. Hey, guys. Good morning. Congrats on the quarter, and thanks so much for taking my questions. I'll start out with two and then get back into the queue. First, it's clear recently that the commercial actions within SAS are having a great effect on FAM and benefiting results there. I'm just curious to hear more about the timeline there and how long you think it'll be until we see the full benefit of that commercial initiative. Secondly, just curious, but I'm wondering if you can provide any additional updates or commentary on the ongoing portfolio review other than what you just mentioned in your prepared remarks. Thanks so much, guys. Thanks, Dan, for your question and kind words. Really appreciate that. Regarding your first question on the actions against regarding FAM. We are starting to see the impact on those financials now. As you heard, year-on-year, quarter-on-quarter, we already have a 4% increase. This was the first quarter of growth in sales and Adjusted EBITDA since the merger. So I'm really pleased with the progress we're making in FAM. Keep in mind that FAM is much more exposed to Europe and the automotive and transportation sectors there, which is, as you know, going through major demand challenges. What the team has done as commercial actions, looking at our HVAC air pollution segments as well as the water filtration segment, we have seen a great pipeline build and very good commercial execution with 20%+ growth in HVAC and air pollution and 10% growth in water filtration. We are also making meaningful progress overall in our films business. We are really starting to close the year-on-year comparison gap. We are regaining share back. Our customers for our premium segments are coming back. Our Asia business is very strong. The change is already materializing, and we expect FAM to perform favorably in Q4 as well. In our second question regarding the strategic portfolio review, as I said in my remarks, we are evaluating opportunities and constantly evaluate those opportunities to strengthen our go-to-market positioning. As you know, we have been evaluating our portfolio ever since the merger, case in point, the EP divestiture about a year and a half ago or so. I will certainly keep you updated on the progress and how we are doing. Be assured that the review is fully encompassing, meaning I talked about footprint rationalization. As a result, we closed our Wilson, North Carolina facility that will be accredited to our EBITDA in 2026. I talked about reviewing our entire R&D portfolio. We optimized the portfolio and have repositioned our resources as well as our portfolio for near-term gains. We reduced complexity by our SKU rationalization, and we are de-layering and making our business more effective and efficient. This review remains a key part of my and the team's focus and the board's focus, and we will absolutely keep you updated as we make further progress. Great. Thanks so much, guys. Thank you very much. Our next question comes from Massimiliano Pilato from Stifel. Your line is now open. Please go ahead. Good morning all, and congrats on the quarter, and thanks for taking my questions. I mean, part of them have already been answered during the prepared remarks, but. Could you please provide. More detail on the relative organic performance in terms of volumes and pricing within the subsegments, and how do you see those growth rates evolve into Q4 and 2026 and the level of visibility of demand into next year? The second question is on the closure of North Carolina facility. I would like to understand if there are any associated costs with the closure and if you could quantify the cost improvements into Q1 2026. Thanks. Maybe I'll kick it off first. Thank you, Massim, for those questions. Regarding the demand, what we saw in Q3, for example, our cable tapes business, especially again with the end-user markets and the big, beautiful bill helping us there, that demand was up. We saw our commercial print segment, as I mentioned, with some of the, with the massive retail chain, we got an increase there. I already touched upon. The water filtration, HVAC. Piece with the data centers. Growth. Talked about released liners. The personal care and hygiene segment there has seen a good demand in Q3. We also saw in our erosion control netting business we are rewinning some of the volume back there. Those areas and some of the segments as examples where we have seen some good improvement in demand through Q3. On the Wilson closure, as I said, it will be accretive to our EBITDA. Regarding the cost, maybe I will let Greg take that one. Yeah. Overall, it represents less than 1% in sales overall. At the time of the closure, we have already recognized some non-cash impairment charges in the current financials. There will be some one-time cash costs with the closure. Overall, yes, accretive to EBITDA and accretive to margins. We should be seeing that flow through at the beginning of 2026. Thank you. Thank you very much. Good luck on the next quarter. Thank you. Our next question comes from Lars Kjellberg with Stifel. Your line is now open. Please go ahead. Thank you for taking my questions, and great to see the good progress you're making. I'm curious about—I mean, you have obviously a new sort of commercial approach that is driving a better price-cost relationship, but at the same time, you seem to be gaining share in the market, which is quite interesting because the market is generally quite soft. Can you sort of describe a bit the mechanics here? What is making you win share in the market given the pricing policies that are driving the margin increase? That would be of interest, driving how those discussions go with your customers. The other thing, with all the various things you're now doing and starting to see clearly the benefit of margin increase, etc., coming through. How should you have a look on 2026 as a whole in terms of compensating for underlying inflation, etc.? With the progress you've seen, should we see a continuation of that towards your 2025—sorry, towards your 15% ultimate target for your margins into 2026 and beyond? Thank you, Lars, for those questions. Let me take the first one. Our commercial execution. I'm really proud of what our sales force is doing. We have really prioritized and focused on our growth initiatives. We have de-layered for faster decision-making. We're really focusing—the sales force is really focused on the growth segment, some of those which I mentioned. We talked about in the past about cross-selling opportunities. These are all being well-supported by our operations. Excellence and supply chain excellence initiatives with better lead times, better service. On-time shipment percentages are better. When you take that full approach, that's how we're able to win in the marketplace and maintain pricing discipline. Greg, if you want to take the— yeah, Lars, maybe I'll try to take the question on the margins and volume. Overall, as we're heading into the fourth quarter, we're expecting—if you take out the currency impact because we're expecting to see a positive currency tailwind in sales again. Outside of that, I'd mentioned we would expect to see SAS volumes up. I do think we'll see much flatter volumes in Q4 year-over-year. With what I shared in terms of expecting the bottom line EBITDA to be up by at least 10%, yes, it does play right into the increasing margins. The path to 15%, we still believe that. We're in businesses that. That's the right target, the 15%. But the path there is. Somewhat gradual. We've seen the improvement from 2023 to 2024 to 2025. We've definitely seen the improvement here in Q2 and 2023. But it will be a gradual. Path to the 15%. We'd expect margins in 2026. We're not providing any specific guidance at this point, but we would expect to see a continuation of that trend of the improved margins in 2026. Thank you. Thank you very much. We currently have no further questions, so I will hand back over to the management team for any closing remarks. Thank you. First, I want to express my sincere gratitude to all the Mativ employees for the dedication and hard work in delivering our Q3 results. Thank you very much. And finally, thanks to all of you for joining us this morning for our earnings call. We look forward to staying connected in the coming months and to welcoming you to our next earnings calls in February. Have a great day, everybody, and thank you for dialing in. Thank you very much, everyone, for joining. That concludes today's call. You may now disconnect your lines.